Barriers to preexposure prophylaxis use among individuals with recently acquired HIV infection in Northern California.
Adult
Anti-HIV Agents
/ administration & dosage
California
/ epidemiology
Ethnicity
/ statistics & numerical data
Female
HIV Infections
/ diagnosis
Health Knowledge, Attitudes, Practice
Homosexuality, Male
/ statistics & numerical data
Humans
Male
Middle Aged
Pre-Exposure Prophylaxis
/ statistics & numerical data
Racial Groups
Sex Distribution
Sexual and Gender Minorities
Surveys and Questionnaires
Young Adult
Human immunodeficiency virus (HIV)
awareness
cost
implementation
preexposure prophylaxis (PrEP)
Journal
AIDS care
ISSN: 1360-0451
Titre abrégé: AIDS Care
Pays: England
ID NLM: 8915313
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
pubmed:
12
10
2018
medline:
7
1
2020
entrez:
12
10
2018
Statut:
ppublish
Résumé
Barriers to HIV preexposure prophylaxis (PrEP) use have not been well-characterized in people who became HIV-infected, all of whom could have benefited from PrEP. We invited Kaiser Permanente Northern California members diagnosed with HIV during 2014-2016, following a negative HIV test in the prior year, to complete a survey assessing barriers to PrEP use before HIV diagnosis. Of 268 patients surveyed, 122 (46%) responded. Median age was 36, most (84%) were men who have sex with men, and 64% were of minority racial/ethnic background. Thirty-six (30%) had discussed PrEP with a provider, of whom 10 were diagnosed with HIV at PrEP intake. Overall, only 5 (4.1%) had used PrEP, and all 5 discontinued before diagnosis. Among all respondents, the most common barrier to PrEP use was lack of PrEP awareness (51%). Among those aware of PrEP, the most common barriers were cost/insurance concerns (36%) and perceived low risk for HIV (24%). Lack of PrEP awareness ranged from 39% among those aged 25-34 to 88% among those aged <25 (P = 0.011), and from 33% among Hispanics to 69% among Blacks (P = 0.055). Increasing awareness and affordability of PrEP, and facilitating accurate assessment of HIV risk, are critical to reducing missed opportunities for PrEP.
Identifiants
pubmed: 30304942
doi: 10.1080/09540121.2018.1533238
pmc: PMC6408235
mid: NIHMS1510005
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
536-544Subventions
Organisme : NIAID NIH HHS
ID : K01 AI122853
Pays : United States
Références
AIDS Behav. 2017 May;21(5):1256-1267
pubmed: 27885552
AIDS Behav. 2018 Nov;22(11):3550-3565
pubmed: 29344740
AIDS Behav. 2018 Nov;22(11):3576-3587
pubmed: 29468493
Sex Transm Dis. 2016 Nov;43(11):717-723
pubmed: 27893604
AIDS Behav. 2018 Nov;22(11):3627-3636
pubmed: 29589137
Clin Infect Dis. 2017 Jan 15;64(2):144-149
pubmed: 27986691
PLoS One. 2017 Feb 21;12(2):e0172354
pubmed: 28222118
AIDS Patient Care STDS. 2017 Dec;31(12):517-527
pubmed: 29211513
Clin Infect Dis. 2018 Jan 6;66(1):149-153
pubmed: 29020316
AIDS Care. 2018 Jan;30(1):9-17
pubmed: 28791876
Int J STD AIDS. 2017 Aug;28(9):849-857
pubmed: 28632468
AIDS Care. 2016 Nov;28(11):1378-85
pubmed: 27136725
Am J Public Health. 2016 Oct;106(10):e2-3
pubmed: 27626355
N Engl J Med. 2012 Aug 2;367(5):423-34
pubmed: 22784038
Prev Sci. 2017 Jul;18(5):505-516
pubmed: 28101813
MMWR Morb Mortal Wkly Rep. 2015 Nov 27;64(46):1291-5
pubmed: 26606148
J Adolesc Health. 2017 May;60(5):549-555
pubmed: 28132744
AIDS Behav. 2016 Jul;20(7):1435-42
pubmed: 26966013
Clin Infect Dis. 2015 Nov 15;61(10):1601-3
pubmed: 26334052
J Acquir Immune Defic Syndr. 2017 Jul 1;75 Suppl 3:S375-S382
pubmed: 28604442
J AIDS Clin Res. 2017 Sep;8(9):
pubmed: 29201531
N Engl J Med. 2010 Dec 30;363(27):2587-99
pubmed: 21091279
AIDS Educ Prev. 2017 Aug;29(4):315-329
pubmed: 28825858
J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):540-546
pubmed: 27851714
J Acquir Immune Defic Syndr. 2017 Oct 1;76(2):132-140
pubmed: 28902677
AIDS Care. 2017 Nov;29(11):1351-1358
pubmed: 28286983
Harm Reduct J. 2017 Jun 29;14(1):40
pubmed: 28662716
N Engl J Med. 2012 Aug 2;367(5):399-410
pubmed: 22784037
Clin Infect Dis. 2018 Aug 31;67(6):965-970
pubmed: 29635415
AIDS Behav. 2018 Nov;22(11):3566-3575
pubmed: 29404756
AIDS Behav. 2018 Jun;22(6):1932-1943
pubmed: 29103191